KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR s Lead Anti-CD47 Candidate in Blood Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
ACCESSWIRE
SON-1010, fully-human IL-12 configured using F
HAB platform, advancing towards IND submission
At-The-Market offering program resulted in net proceeds of $10.2 million
PRINCETON, NJ / ACCESSWIRE / May 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ( Sonnet or the Company ), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended March 31, 2021 and provided a business update. Over the course of the quarter, we have made several advancements across our pipeline products, most notably of which are the completion of non-human primate (NHP) toxicology study of SON-080 and the completion of a repeat dose study of SON-1010 in NHPs, commented Pankaj Mohan, Ph.D., Founder and CEO. Additionally, we were thrilled to have our abstract detailing data from our NHP study of SON-1010 accep
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
ACCESSWIRE
10 May 2021, 20:43 GMT+10
The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome.
Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-F
HAB over recombinant human IL-12, with a half-life around 40 hours in NHP.
A significant increase in Interferon-γ, a key pleiotropic cytokine associated with anti-tumor mechanisms, was observed following dosing with IL12-F
HAB.
/
May 10, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has completed a successful preclinical nonhuman primate (NHP) GLP repeat-dose study of SON-1010, a proprietary version of Interleukin 12
Press release content from Accesswire. The AP news staff was not involved in its creation.
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
May 3, 2021 GMT
New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territoriesUpfront and potential milestone payments totaling up to $21 Million with up to 30% royalties on commercial salesNLT to fund Phase .
New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territoriesUpfront and potential milestone payments totaling up to $21 Million with up to 30% royalties on commercial salesNLT to fund Phase .
New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.